Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug ...
Tags: Alzheon, Alzheimer's Disease
Optivia Biotechnology has secured a $1.8m two-year Phase II small business innovation research (SBIR) grant, from the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH). The federal grant is expected to ...
Japanese pharmaceutical firm Eisai has secured approval from the European Commission (EC) on the license extension application for the use of antiepileptic agent Zonegran (zonisamide) in the treatment of pediatric patients. The EC ...
Tags: Eisai Obtains, Zonegran
Health Canada has accepted to review Sunovion Pharmaceuticals Canada's (Sunovion) new drug submission (NDS) for eslicarbazepine acetate for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients aged ...
Plexcera Therapeutics has received approval from Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine, to develop recombinant human acid ceramidase (rhAC) for treatment of diseases caused by genetic or ...
Tags: Plexcera, Cystic Fibrosis
Specialty pharmaceutical company Supernus has launched Trokendi XR, its once-daily extended release formulation of topiramate, for the treatment of epilepsy in the US. As of now, Trokendi XR has been shipped to major wholesalers in the ...
US-based specialty pharmaceutical firm Upsher-Smith Laboratories will launch the generic version of its Morphine Sulfate extended-release (ER) capsules, CII on 4 September 2013. Morphine Sulfate ER Capsules, CII are currently available in ...
Tags: ER Capsules, pharmaceutical
NeuroSigma has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin a Phase III pivotal trial of its Monarch eTNS System. Designed to treat the drug resistant epilepsy, the ...
Tags: Device Trial, NeuroSigma
Researchers from Boston and Oregon have developed a silk implant that may help stop the progression of epilepsy. This biodegradable implant is designed to release adenosine, a specific chemical compound when placed in the brain. ...
Tags: Silk Implants, Epilepsy
The USFDA has cleared Actavis' abbreviated new drug application (ANDA) for Lamotrigine orally disintegrating tablets, 25mg, 50mg, 100mg and 200mg. A generic version of GlaxoSmithKline's Lamictal ODT, the antiepileptic drug is indicated ...
The US Food & Drug Administration (FDA) has issued a tentative approval letter to Supernus Pharmaceuticals for its Trokendi XR (extended release topiramate) in the treatment of epilepsy. Following to completion of review of the Trokendi ...
Tags: Supernus Trokendi, FDA Approval
KNOXVILLE, Tenn., June 6, 2013 /PRNewswire-iReach/ -- On Saturday, June 15th the Knoxville, TN Stanton Optical store is having a customer appreciation celebration from Noon until 3:00 PM. General Manager Juan Jonny Lopez and Sales Manager ...
UCB and IBM have announced the completion of the initial phase of project designed to exploit super-computer power for better care for epilepsy patients. The power of cognitive computing capabilities, such as IBM's Watson, will be ...
The US Food and Drug Administration (FDA) has warned the people that the anti-seizure drug, Potiga, developed by Valeant Pharmaceuticals and co-marketed with GlaxoSmithKline, may cause eye and skin problems. FDA warned that Potiga may ...
Tags: Anti-Seizure Drug Potiga, Medicine
The University of Pennsylvania, MIT and the University of Illinois at Champaign-Urbana are in the process of creating a surreal design involving LEDs, implants and tattoos. Researchers are working to create an implant that uses ...
Tags: LED Tattoo, LED, Lights, Lighting